Spots Global Cancer Trial Database for metastatic ovarian carcinoma

Every month we try and update this database with for metastatic ovarian carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer	NCT04703920	Metastatic Brea... Metastatic Cast... Metastatic Ovar...	Talazoparib Belinostat	18 Years -	University of Michigan Rogel Cancer Center
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	NCT04514484	Advanced Differ... Advanced Head a... Advanced Hepato... Advanced Kaposi... Advanced Lung N... Advanced Lung S... Advanced Malign... Advanced Melano... Advanced Ovaria... Advanced Prosta... Advanced Renal ... Advanced Thyroi... Advanced Triple... Advanced Urothe... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Clinical Stage ... Clinical Stage ... HIV Infection Metastatic Diff... Metastatic Head... Metastatic Hepa... Metastatic Kapo... Metastatic Lung... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Pros... Metastatic Rena... Metastatic Thyr... Metastatic Trip... Metastatic Urot... Recurrent Diffe... Recurrent Head ... Recurrent Hepat... Recurrent Kapos... Recurrent Lung ... Recurrent Lung ... Recurrent Malig... Recurrent Melan... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Thyro... Recurrent Tripl... Recurrent Uroth... Refractory Diff... Stage III Diffe... Stage III Hepat... Stage III Lung ... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Thyro... Stage IV Differ... Stage IV Hepato... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Thyroi...	Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax	NCT05092373	Advanced Breast... Advanced Endome... Advanced Fallop... Advanced Hepato... Advanced Malign... Advanced Malign... Advanced Malign... Advanced Ovaria... Advanced Primar... Advanced Renal ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Malignant Abdom... Malignant Solid... Metastatic Brea... Metastatic Endo... Metastatic Fall... Metastatic Hepa... Metastatic Mali... Metastatic Mali... Metastatic Mali... Metastatic Ovar... Metastatic Prim... Metastatic Rena... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Fallo... Stage III Hepat... Stage III Ovari... Stage III Prima... Stage III Renal... Stage III Uteri... Stage IIIA Fall... Stage IIIA Hepa... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIA Uter... Stage IIIA1 Fal... Stage IIIA1 Ova... Stage IIIA2 Fal... Stage IIIA2 Ova... Stage IIIB Fall... Stage IIIB Hepa... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIB Uter... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Fallop... Stage IV Hepato... Stage IV Ovaria... Stage IV Primar... Stage IV Renal ... Stage IV Uterin... Stage IVA Fallo... Stage IVA Hepat... Stage IVA Ovari... Stage IVA Prima... Stage IVA Uteri... Stage IVB Fallo... Stage IVB Hepat... Stage IVB Ovari... Stage IVB Prima... Stage IVB Uteri...	Atezolizumab Cabozantinib S-... Nab-paclitaxel Tumor Treating ...	18 Years -	M.D. Anderson Cancer Center
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02627443	Metastatic Fall... Metastatic Ovar... Metastatic Prim... Ovarian Endomet... Ovarian High Gr... Platinum-Sensit... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Berzosertib Carboplatin Gemcitabine Hyd... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	NCT04673448	Anatomic Stage ... Anatomic Stage ... BRCA-Associated... BRCA-Associated... Metastatic BRCA... Metastatic Brea... Metastatic Fall... Metastatic Mali... Metastatic Ovar... Metastatic Panc... Metastatic Prim... Prognostic Stag... Prognostic Stag... Stage III Fallo... Stage III Ovari... Stage III Pancr... Stage III Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Pancre... Stage IV Primar... Unresectable Br... Unresectable Fa... Unresectable Ma... Unresectable Ov... Unresectable Pa... Unresectable Pr...	Dostarlimab Niraparib	18 Years -	University of Washington
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer	NCT04329494	Clinical Stage ... Clinical Stage ... Clinical Stage ... Malignant Uteri... Metastatic Appe... Metastatic Colo... Metastatic Gast... Metastatic Mali... Metastatic Mali... Metastatic Ovar... Pathologic Stag... Peritoneal Carc... Postneoadjuvant... Stage IV Append... Stage IV Colore... Stage IV Ovaria... Stage IV Uterin... Stage IVA Appen... Stage IVA Color... Stage IVA Ovari... Stage IVA Uteri... Stage IVB Appen... Stage IVB Color... Stage IVB Ovari... Stage IVB Uteri... Stage IVC Appen... Stage IVC Color...	Biopsy Cisplatin Doxorubicin Fluorouracil Intraperitoneal... Irinotecan Leucovorin Mitomycin Oxaliplatin Quality-of-Life... Questionnaire A...	18 Years -	City of Hope Medical Center
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02627443	Metastatic Fall... Metastatic Ovar... Metastatic Prim... Ovarian Endomet... Ovarian High Gr... Platinum-Sensit... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Berzosertib Carboplatin Gemcitabine Hyd... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors	NCT05733000	Advanced Biliar... Advanced Colore... Advanced Gastro... Advanced Lung A... Advanced Malign... Advanced Ovaria... Advanced Pancre... Advanced Urothe... Clinical Stage ... Clinical Stage ... Metastatic Bili... Metastatic Colo... Metastatic Gast... Metastatic Lung... Metastatic Ovar... Metastatic Panc... Metastatic Urot... Refractory Bili... Refractory Colo... Refractory Gast... Refractory Lung... Refractory Ovar... Refractory Panc... Refractory Urot... Stage II Pancre... Stage III Color... Stage III Lung ... Stage III Ovari... Stage III Pancr... Stage IV Colore... Stage IV Lung C... Stage IV Ovaria... Stage IV Pancre...	Biospecimen Col... Computed Tomogr... Devimistat Fluorouracil Gemcitabine Hyd... Hydroxychloroqu... Magnetic Resona...	18 Years -	Northwestern University
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors	NCT05075993	Metastatic Esop... Gastric Cancer Metastatic Head... Metastatic Hepa... Metastatic HPV ... Metastatic Ovar... Metastatic Soft... Metastatic Uvea...	LVGN3616 + LVGN... LVGN3616 + LVGN... LVGN3616 + LVGN... LVGN3616 + LVGN...	18 Years -	M.D. Anderson Cancer Center
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer	NCT02298959	Clinical Stage ... Metastatic Colo... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Rena... Platinum-Resist... Recurrent Melan... Recurrent Renal... Refractory Mela... Refractory Rena... Sarcoma Stage IV Colore... Stage IV Ovaria... Stage IV Renal ...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Pembrolizumab Ziv-Aflibercept	18 Years -	National Cancer Institute (NCI)
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis	NCT03508570	Malignant Perit... Malignant Retro... Metastatic Cerv... Metastatic Endo... Metastatic Fall... Metastatic Mali... Metastatic Ovar... Metastatic Prim... Peritoneal Carc... Platinum-Refrac... Platinum-Refrac... Platinum-Refrac... Platinum-Refrac... Platinum-Resist... Platinum-Resist... Platinum-Resist... Platinum-Resist... Recurrent Cervi... Recurrent Endom... Recurrent Fallo... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IVA Fallo... Stage IVA Ovari... Stage IVA Prima... Stage IVB Cervi... Stage IVB Fallo... Stage IVB Ovari... Stage IVB Prima... Stage IVB Uteri...	Ipilimumab Laboratory Biom... Nivolumab Pharmacokinetic...	18 Years -	M.D. Anderson Cancer Center
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer	NCT02298959	Clinical Stage ... Metastatic Colo... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Rena... Platinum-Resist... Recurrent Melan... Recurrent Renal... Refractory Mela... Refractory Rena... Sarcoma Stage IV Colore... Stage IV Ovaria... Stage IV Renal ...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Pembrolizumab Ziv-Aflibercept	18 Years -	National Cancer Institute (NCI)
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis	NCT03508570	Malignant Perit... Malignant Retro... Metastatic Cerv... Metastatic Endo... Metastatic Fall... Metastatic Mali... Metastatic Ovar... Metastatic Prim... Peritoneal Carc... Platinum-Refrac... Platinum-Refrac... Platinum-Refrac... Platinum-Refrac... Platinum-Resist... Platinum-Resist... Platinum-Resist... Platinum-Resist... Recurrent Cervi... Recurrent Endom... Recurrent Fallo... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IVA Fallo... Stage IVA Ovari... Stage IVA Prima... Stage IVB Cervi... Stage IVB Fallo... Stage IVB Ovari... Stage IVB Prima... Stage IVB Uteri...	Ipilimumab Laboratory Biom... Nivolumab Pharmacokinetic...	18 Years -	M.D. Anderson Cancer Center
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations	NCT04550494	Advanced Pancre... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Clinical Stage ... Clinical Stage ... HER2-Positive B... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Brea... Metastatic Gast... Metastatic Mali... Metastatic Ovar... Metastatic Panc... Metastatic Pros... Platinum-Sensit... Stage II Pancre... Stage III Ovari... Stage III Pancr... Stage III Prost... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Talazoparib	18 Years -	National Cancer Institute (NCI)
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer	NCT04498520	Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Hormone Recepto... Locally Advance... Metastatic Brea... Metastatic Endo... Metastatic Fall... Metastatic HER2... Metastatic Mali... Metastatic Ovar... Metastatic Prim... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Refractory Brea... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IV Uterin... Stage IVA Fallo... Stage IVA Ovari... Stage IVA Prima... Stage IVA Uteri... Stage IVB Fallo... Stage IVB Ovari... Stage IVB Prima... Stage IVB Uteri...	Abexinostat Tos... Fulvestrant Palbociclib	18 Years -	University of California, San Francisco
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer	NCT04498520	Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Hormone Recepto... Locally Advance... Metastatic Brea... Metastatic Endo... Metastatic Fall... Metastatic HER2... Metastatic Mali... Metastatic Ovar... Metastatic Prim... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Refractory Brea... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IV Uterin... Stage IVA Fallo... Stage IVA Ovari... Stage IVA Prima... Stage IVA Uteri... Stage IVB Fallo... Stage IVB Ovari... Stage IVB Prima... Stage IVB Uteri...	Abexinostat Tos... Fulvestrant Palbociclib	18 Years -	University of California, San Francisco
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer	NCT02298959	Clinical Stage ... Metastatic Colo... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Rena... Platinum-Resist... Recurrent Melan... Recurrent Renal... Refractory Mela... Refractory Rena... Sarcoma Stage IV Colore... Stage IV Ovaria... Stage IV Renal ...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Pembrolizumab Ziv-Aflibercept	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: